Periscope Capital Inc. acquired a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $1,527,000.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Drugs Made In America Acquisition II in the first quarter worth $19,960,000. First Trust Capital Management L.P. bought a new stake in shares of Drugs Made In America Acquisition II in the third quarter valued at $13,218,000. Wealthspring Capital LLC purchased a new position in shares of Drugs Made In America Acquisition II during the 3rd quarter valued at $4,063,000. Kryger Capital LLC purchased a new position in shares of Drugs Made In America Acquisition II during the 1st quarter valued at $3,088,000. Finally, Rivernorth Capital Management LLC purchased a new position in shares of Drugs Made In America Acquisition II during the 1st quarter valued at $2,991,000.
Drugs Made In America Acquisition II Trading Up 0.0%
NASDAQ:DMII opened at $10.24 on Monday. The business’s fifty day moving average is $10.19 and its 200 day moving average is $10.08. Drugs Made In America Acquisition II Corp. has a 52-week low of $9.86 and a 52-week high of $10.33.
Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported $0.07 EPS for the quarter.
Analyst Ratings Changes
DMII has been the subject of several research reports. Wall Street Zen upgraded Drugs Made In America Acquisition II to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Research Report on DMII
Drugs Made In America Acquisition II Company Profile
Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.
Further Reading
- Five stocks we like better than Drugs Made In America Acquisition II
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding DMII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report).
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
